Fluorophore-conjugated Helicobacter pylori recombinant membrane protein (HopQ) labels primary colon cancer and metastases in orthotopic mouse models by binding CEA-related cell adhesion molecules.
Journal
Translational oncology
ISSN: 1936-5233
Titre abrégé: Transl Oncol
Pays: United States
ID NLM: 101472619
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
09
06
2020
revised:
10
08
2020
accepted:
12
08
2020
pubmed:
1
9
2020
medline:
1
9
2020
entrez:
1
9
2020
Statut:
ppublish
Résumé
HopQ is an outer-membrane protein of Helicobacter pylori that binds to human carcinoembryonic antigen-related cell-adhesion molecules (CEACAMs) with high specificity. We aimed to investigate fluorescence targeting of CEACAM-expressing colorectal tumors in patient-derived orthotopic xenograft (PDOX) models with fluorescently labeled recombinant HopQ (rHopQ). Western blotting, flow cytometry and ELISA were performed to determine the efficiency of rHopQ binding to CEACAMs. rHopQ was conjugated to IR800DyeCW (rHopQ-IR800). Nude mice received orthotopic implantation of colon cancer tumors. Three weeks later, mice were administered 25 μg or 50 μg HopQ-IR800 and imaged 24 or 48 h later. Intravital images were analyzed for tumor-to-background ratio (TBR). Flow cytometry and ELISA demonstrated binding of HopQ to CEACAM1, 3 and 5. Dose-response intravital imaging in PDOX models demonstrated optimal results 48 h after administration of 50 μg rHopQ-IR800 (TBR = 3.576) in our protocol. Orthotopic models demonstrated clear tumor margins of primary tumors and small regional metastases with a mean TBR = 3.678 (SD ± 1.027). rHopQ showed specific binding to various CEACAMs in PDOX models. rHopQ may be useful for CEACAM-positive tumor and metastasis detection for pre-surgical diagnosis, intra-operative imaging and fluorescence-guided surgery.
Identifiants
pubmed: 32866936
pii: S1936-5233(20)30349-1
doi: 10.1016/j.tranon.2020.100857
pmc: PMC7475271
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100857Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest Dr. Hoffman is a non-salaried affiliate of AntiCancer Inc., which used PDOX models for contract research. All other authors have no conflicts of interest to disclose.
Références
Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9345-9
pubmed: 1924398
Cell Microbiol. 2019 Jan;21(1):e12965
pubmed: 30321907
JAMA Surg. 2015 Sep;150(9):890-8
pubmed: 26132363
Cancer Metastasis Rev. 2013 Dec;32(3-4):643-71
pubmed: 23903773
Curr Opin Cell Biol. 2006 Oct;18(5):565-71
pubmed: 16919437
Semin Cancer Biol. 1999 Apr;9(2):67-81
pubmed: 10202129
Proc SPIE Int Soc Opt Eng. 2020 Feb;11222:
pubmed: 32255887
J Surg Oncol. 2016 Dec;114(8):951-958
pubmed: 27696448
EMBO J. 2018 Jul 2;37(13):
pubmed: 29858229
Nat Microbiol. 2016 Oct 17;2:16189
pubmed: 27748768
Oncotarget. 2020 Jan 28;11(4):429-439
pubmed: 32064046
J Surg Oncol. 2014 Apr;109(5):451-8
pubmed: 24249594
Nat Microbiol. 2016 Oct 31;2:16233
pubmed: 27798561
Cancers (Basel). 2019 Mar 13;11(3):
pubmed: 30871206
J Surg Oncol. 2015 Aug;112(2):119-24
pubmed: 26266663
Gut. 2017 Apr;66(4):683-691
pubmed: 26818619
Anal Chem. 2011 Aug 15;83(16):6336-41
pubmed: 21721569
Acta Oncol. 2010 Jun;49(5):578-607
pubmed: 20491524
PLoS One. 2010 Jan 18;5(1):e8747
pubmed: 20090913
J Surg Res. 2013 Jan;179(1):87-93
pubmed: 23079571
J Laparoendosc Adv Surg Tech A. 2014 Apr;24(4):241-7
pubmed: 24494971
Br J Cancer. 2013 Feb 19;108(3):662-7
pubmed: 23322207